Serum ferritin predicts response to tocilizumab in glucocorticoid-resistant adult-onset Still's disease: a prospective real-world cohort study.
OBJECTIVES To evaluate the real-world effectiveness and safety of tocilizumab (TCZ) in glucocorticoid (GC)-resistant adult-onset Still's disease (AOSD) and explore predictors of clinical response. METHODS This prospective, single-centre cohort study enrolled consecutive eligible patients with GC-resistant AOSD who in...